Table 7.
Scenario analysis results.
| Absolute | Incremental | Absolute | Incremental | |||||
|---|---|---|---|---|---|---|---|---|
| PER 8 mg/day | LCM 400 mg/day | Change% | PER 4 mg/day | LCM 200 mg/day | Change% | |||
| Seizures | 530 | 633 | −103 | −16.23 | 854 | 873 | −19 | −2.16 |
| LYs | 4.912 | 4.868 | 0.044 | 0.90 | 5.122 | 5.127 | −0.005 | −0.09 |
| QALYs | 3.111 | 3.072 | 0.039 | 1.24 | 3.233 | 3.238 | −0.005 | −0.16 |
| Drug costs | 7,198 | 9,947 | −2,749 | −27.63 | 5,800 | 6,496 | −696 | −10.71 |
| Medical costs | 7,137 | 7,135 | 2 | 0.03 | 7,649 | 7,507 | 142 | 1.89 |
| Total costs | 14,335 | 17,082 | −2,747 | −16.08 | 13,449 | 1,4003 | −554 | −3.95 |
| ICER per seizure avoided ($/seizure) | 29.41 | |||||||
| ICER per LY ($/year) | 116,275.56 | |||||||
| ICER per QALY ($/QALY) | 105,193.94 | |||||||
PER, perampanel; LCM, lacosamide; LY, life year; QALY, quality-adjusted life years; ICER, incremental cost-effectiveness ratio.